BioCardia, Inc. reported filing a second Investigational Device Exemption with the Food and Drug Administration (FDA) for the CardiAMP Chronic Myocardial Ischemia Trial to treat patients with refractory angina. This second potential indication for CardiAMP investigational cell therapy of chronic myocardial ischemia (CMI) and refractory angina follows the company’s FDA-approved Phase III clinical trial of CardiAMP in ischemic heart failure, which is currently enrolling patients. The CardiAMP investigational therapy takes a personalized and minimally-invasive approach to the use of a patient’s own cells (autologous cells) in the treatment of CMI. The investigational therapy is designed to stimulate the body’s natural healing response.